Use of rats mesenchymal stem cells modified with mHCN2 gene to create biologic pacemakers

Abstract

The possibility of rats mesenchymal stem cells (MSCs) modified with murine hyperpolarization-activated cyclic nucleotide-gated 2 (mHCN2) gene as biological pacemakers in vitro was studied. The cultured MSCs were transfected with pIRES2-EGFP plasmid carrying enhanced green fluorescent protein (EGFP) gene and mHCN2 gene. The identification using restriction enzyme and sequencing indicated that the mHCN2 gene was inserted to the pIRES2-EGFP. Green fluorescence could be seen in MSCs after transfection for 24–48 h. The expression of mHCN2 mRNA and protein in the transfected cells was detected by RT-PCR and Western blot, and the quantity of mHCN2 mRNA and protein expression in transfected MSCs was 5.31 times and 7.55 times higher than that of the non-transfected MSCs respectively (P<0.05, P<0.05). I_HCN2 was recorded by whole-cell patch clamp method. The effect of Cs⁺, a specific blocker of pacemaker current, was measured after perfusion by patch clamp. The results of inward current indicated that there was no inward current recording in non-transfected MSCs and a large voltage-dependent inward and Cs⁺-sensitive current activated on hyperpolarizations presented in the transfected MSCs. I_HCN2 was fully activated around −140 mV with an activation threshold of −60 mV. The midpoint (V₅₀) was −95.1±0.9 mV (n=9). The study demonstrates that mHCN2 mRNA and protein can be expressed and the currents of HCN2 channels can be detected in genetically modified MSCs. The gene-modified MSCs present a novel method for pacemaker genes into the heart or other electrical syncytia.

Keywords

stem cells / gene therapy / hyperpolarization-activated cyclic nucleotide-gated / pacemaker current

References

[1] EdelbergJ.M., AirdW.C., RosenbergR.D.. Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest, 1998, 101(2): 337-343

[2] GlennC.M., PogwizdS.M.. Gene therapy to develop a genetically engineered cardiac pacemaker. J Cardiovasc Nurs, 2003, 18(5): 330-336

[3] QuJ., PlotnikovA.N., DaniloP.Jr, et al.. Expression and function of a biological pacemaker in canine heart. Circulation, 2003, 7(8): 1106-1109

[4] PlotnikovA.N., SosunovE.A., QuJ., et al.. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation, 2004, 109(4): 506-512

[5] HammA., KrottN., BreibachI., et al.. Efficient transfection method for primary cells. Tissue Eng, 2002, 8: 235-245

[6] GepsteinL.. Derivation and potential application of human embryonic stem cells. Circulation Research, 2002, 91(10): 866-876

[7] SchafflerA., BuchlerC.. Concise review: Adipose tissue-derived stromal cells-Basic and clinical implications for novel cell-based therapies. Stem Cells, 2007, 25(4): 818-827

[8] HoffmanL.M., CarpenterM.K.. Characterization and culture of human embryonic stem cells. Nat Biotechnol, 2005, 23(6): 699-708

[9] Wislet-GendebienS., HansG., LeprinceP., et al.. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells, 2005, 23(3): 392-402

[10] OhnishiS., NagayaN.. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure. Am J Nephrol, 2007, 27(3): 301-307

[11] LiuF.H., YangD.Z., WangY.F., et al.. Isolation and culture of mouse marrow mesenchymal stem cells (MSCs) and biological characteristics of MSCs cultured in conditions for spermatogonia in vitro. Zhonghua Nan Ke Xue (Chinese), 2005, 11(5): 350-355

[12] HeubachJ.F., GrafE.M., LeutheuserJ., et al.. Electrophysiological properties of human mesenchymal stem cells. J Physiol, 2004, 554(3): 659-672

[13] PotapovaI., PlotnikovA., LuZ., et al.. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res, 2004, 94(7): 952-959

[14] OhnishiS., NagayaN.. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure. Am J Nephrol, 2007, 27(3): 301-307

[15] GuoL., KawazoeN., FanY., et al.. Chondrogenic differentiation of human mesenchymal stem cells on photoreactive polymer-modified surfaces. Biomaterials, 2008, 29(1): 23-32

[16] GuillotP., CookH., PuseyC., et al.. Transplantation of human fetal mesenchymal stem cells improves glomerulopathy in a collagen type Ialpha2-deficient mouse. J Pathol, 2008, 214(5): 627-636

[17] DiFrancescoD., BorerJ.S.. The funny current: cellular basis for the control of heart rate. Drugs, 2007, 67(2): 15

[18] BaruscottiM., RobinsonR.B.. Electrophysiology and pacemaker function of the developing sinoatrial node. Am J Physiol Heart Circ Physiol, 2007, 293(5): H2613-H2623

[19] XiaoY.F., SiggD.C.. Biological approaches to generating cardiac biopacemaker for bradycardia. Acta Physiologica Sinica, 2007, 59(5): 562-570

[20] LiuJ., DobrzynskiH., YanniJ., et al.. Organization of the mouse sinoatrial node: structure and expression of HCN channels. Cardiovasc Res, 2007, 73(4): 729

[21] NiemeyerP., KrauseU., KastenP., et al.. Mesenchymal stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage. Curr Stem Cell Res Ther, 2006, 1(1): 21-27

[22] StieberJ., HerrmannS., FeilS., et al.. The hyperpolarization-activated channel HCN4 is required for the generation of pacemaker action potentials in the embryonic heart. Proc Natl Acad Sci USA, 2003, 100(25): 15 235-15 240